Skip to main content

Table 2 Sample size requirements per trial arm, for three hypothetical trial scenarios, comparing differences between using DVR/SUVR, a cortical/early composite ROI, and restricting the inclusion to APOE-ε4 carriers or not

From: Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging

 

Whole population

APOE- ε4 carriers only

SUVR

DVR

SUVR

DVR

Cortical ROI

Early ROI

Cortical ROI

Early ROI

Cortical ROI

Early ROI

Cortical ROI

Early ROI

Secondary prevention to detect 20% reduction in accumulation (CL > 20.1)

176

167

143

140

116

125

83

97

Early secondary prevention to detect 20% reduction in accumulation (20.1 < CL ≤ 49.4)

44

51

39

38

52

56

47

43

Primary prevention to detect 20% reduction in accumulation (CL ≤ 20.1)

855

509

1508

734

724

455

1162

630